| PTO Form 1553 (Rev 9/2005) |
| OMB No. 0651-0054 (Exp. 10/31/2017) |
Trademark/Service Mark Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
| SERIAL NUMBER |
85442528 |
| LAW OFFICE ASSIGNED |
LAW OFFICE 116 |
| EXTENSION OF USE |
NO |
| MARK SECTION |
| MARK |
http://uspto.report/TM/85442528/mark.png |
| LITERAL ELEMENT |
CERULEAN |
| STANDARD CHARACTERS |
YES |
| USPTO-GENERATED IMAGE |
YES |
| MARK STATEMENT |
The mark consists of standard characters, without claim to any particular font style, size or color. |
| OWNER SECTION |
| NAME |
Cerulean Pharma Inc. |
| STREET |
840 Memorial Drive, 5th Floor |
| CITY |
Cambridge |
| STATE |
Massachusetts |
| ZIP/POSTAL CODE |
02139 |
| COUNTRY |
United States |
| GOODS AND/OR SERVICES SECTION |
| INTERNATIONAL CLASS |
005 |
| CURRENT IDENTIFICATION |
pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers
or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign
cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical
preparations for use in the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which
facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including
pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders, all containing nanometer size
compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate
targeting or delivery of the active ingredient |
| GOODS OR SERVICES DELETED FROM THE APPLICATION |
, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; inflammation and inflammatory diseases
or disorders, and cardiovascular diseases or disorders, |
| GOODS OR SERVICES IN USE IN COMMERCE |
pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant
cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and
benign cancers or neoplasms; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations for use in the diagnosis, prognosis and prevention of oncological diseases or
disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in
the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms, all containing nanometer size
compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate
targeting or delivery of the active ingredient |
| FIRST USE ANYWHERE DATE |
05/21/2012 |
| FIRST USE IN COMMERCE DATE |
05/21/2012 |
| SPECIMEN FILE NAME(S) |
| ORIGINAL PDF FILE |
SPN0-631381729-20141112173534348850_._F1562212.PDF |
CONVERTED PDF FILE(S)
(1 page) |
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml17\SOU0002.JPG |
| SPECIMEN DESCRIPTION |
Clinical trial label |
| REQUEST TO DIVIDE |
NO |
| PAYMENT SECTION |
| NUMBER OF CLASSES IN USE |
1 |
| SUBTOTAL AMOUNT [ALLEGATION OF USE FEE] |
100 |
| TOTAL AMOUNT |
100 |
| SIGNATURE SECTION |
| ORIGINAL PDF FILE |
hw_631381729-173534348_._F1561597.PDF |
CONVERTED PDF FILE(S)
(2 pages) |
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml17\SOU0003.JPG |
| |
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml17\SOU0004.JPG |
| SIGNATORY'S NAME |
Alejandra Carvajal |
| SIGNATORY'S POSITION |
VP, General Counsel |
| FILING INFORMATION |
| SUBMIT DATE |
Wed Nov 12 17:41:43 EST 2014 |
| TEAS STAMP |
USPTO/SOU-XX.XXX.XXX.X-20
141112174143103582-854425
28-500e0a9cc29121703c3216
78ac33dc9bd29e28af546944e
75893ba8947a9b75c34-DA-44
75-20141112173534348850 |
| PTO Form 1553 (Rev 9/2005) |
| OMB No. 0651-0054 (Exp. 10/31/2017) |
Trademark/Service Mark Statement of Use
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: CERULEAN(Standard Characters, see http://uspto.report/TM/85442528/mark.png)
SERIAL NUMBER: 85442528
The applicant, Cerulean Pharma Inc., having an address of
840 Memorial Drive, 5th Floor
Cambridge, Massachusetts 02139
United States
is submitting the following allegation of use information:
For International Class 005:
Current identification: pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers or neoplasms; pharmaceutical
preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms,
inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations for use in
the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which facilitate targeting or delivery
of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders
and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders, all containing nanometer size compounds which facilitate targeting or
delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate targeting or delivery of the active
ingredient
This
allegation of use does
NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these
goods/services are
permanently deleted: , inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; inflammation and inflammatory diseases or disorders,
and cardiovascular diseases or disorders,
The mark is in use in commerce on or in connection with the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class:
pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers or neoplasms; pharmaceutical preparations for use in
the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms; pharmaceutical preparations for
use in modulating angiogenesis; pharmaceutical preparations for use in the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all
containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of
oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms, all containing nanometer size compounds which facilitate targeting or delivery of the
active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate targeting or delivery of the active ingredient
The mark was first used by the applicant, or the applicant's related company, licensee, or predecessor in interest at least as early as 05/21/2012, and first used in commerce at least as early as
05/21/2012, and is now in use in such commerce. The applicant is submitting one specimen for the class showing the mark as used in commerce on or in connection with any item in the class, consisting
of a(n) Clinical trial label.
Original PDF file:
SPN0-631381729-20141112173534348850_._F1562212.PDF
Converted PDF file(s) (1 page)
Specimen File1
The applicant is not filing a Request to Divide with this Allegation of Use form.
A fee payment in the amount of $100 will be submitted with the form, representing payment for the allegation of use for 1 class.
Declaration
Original PDF file:
hw_631381729-173534348_._F1561597.PDF
Converted PDF file(s) (2 pages)
Signature File1
Signature File2
Signatory's Name: Alejandra Carvajal
Signatory's Position: VP, General Counsel
RAM Sale Number: 85442528
RAM Accounting Date: 11/13/2014
Serial Number: 85442528
Internet Transmission Date: Wed Nov 12 17:41:43 EST 2014
TEAS Stamp: USPTO/SOU-XX.XXX.XXX.X-20141112174143103
582-85442528-500e0a9cc29121703c321678ac3
3dc9bd29e28af546944e75893ba8947a9b75c34-
DA-4475-20141112173534348850
